Exhibit 99.1 Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights • Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune compromise • Reported interim exploratory COVID-19 clinical event data from CANOPY Phase 3 clinical trial of VYD222 • Received product-specific reimbursement codes covering PEMGARDA from the U.S. Centers for Medicare & Medicaid Services (CMS), covering approximately half ...